Business By Kate Sheridan Prescription apps are gaining ground — and drug makers’ backing — as digital therapeutics
Off the Charts By Jennifer Adaeze Okwerekwu ‘The fallout has been all around me’: How becoming a doctor has taken a mental toll
First Opinion By Kate G. Farber and Charles H. Kellner Don’t call electroconvulsive therapy ‘shock therapy’
Health By Joseph P. Kahn — Boston Globe Tracking the risks and rewards of transcranial magnetic stimulation
Quick Take By Eric Boodman The science of heartbreak: A loved one’s death boosts risk of cardiac arrhythmia
First Opinion By Patrick Skerrett Depression screening for adults and adolescents has benefits, but don’t ignore the downsides
Business By Rebecca Robbins This antidepressant may be no better than cheaper alternatives. But demand could soon soar
In the Lab By Megan Thielking Scientists seek fast-acting antidepressant, from ketamine to laughing gas
First Opinion By Frances Southwick ‘A painful facade’: My battle with depression as a medical resident